Literature DB >> 20923498

Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with Type 2 diabetes mellitus.

Mustafa Temizel1, Meral Mert, Celal Bozbey, Yücel Arman, Ertan Cevizci, Nejat Altintaş, Ali Cetin Ölek.   

Abstract

BACKGROUND: Weight gain is a significant problem in diabetic patients in terms of worsening glycemic control, increasing diabetic and cardiovascular morbidity and mortality, and contributing to social and psychological problems. In the present study, we evaluated the effects of a biphasic analog and regular NPH insulin mixtures on weight gain in patients with Type 2 diabetes mellitus (T2DM) over 1 year.
METHODS: Group I consisted of 71 patients (29 men and 42 women) being treated with analog mixtures (insulin lispro 75/25 mix and biphasic insulin aspart 70/30 mix) twice daily; Group II consisted of 69 patients (23 men and 46 women) being treated with a regular insulin mixture (70/30) twice daily. Starting weight, body mass index, HbA1c, and hypoglycemic episodes were evaluated after 6 and 12 months.
RESULTS: Weight gain in Group I at 6 and 12 months was 1.41 ± 2.70 and 2.08 ± 3.74 kg, respectively. In Group II, weight gain at 6 and 12 months was 1.5 ± 3.0 and 2.29 ± 3.85 kg, respectively. Intragroup comparisons indicated that, for both groups, weight gain at 6 and 12 months differed significantly from the starting weight. However, no significant differences in weight gain were found between the two groups (P > 0.05).
CONCLUSIONS: The weight-increasing effects of an analog mixture of insulin and the NPH regular mixture of insulin appear to be similar. This should be taken into account when determining the type of insulin to use in treating T2DM patients.
© 2010 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923498     DOI: 10.1111/j.1753-0407.2010.00080.x

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  4 in total

Review 1.  Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Authors:  Andreas Liebl; Vinay Prusty; Paul Valensi; Ryuzo Kawamori; Jens Sandahl Christiansen; Andrew J Palmer; Per Balschmidt; Robert Ligthelm; Viswanathan Mohan
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A1chieve study.

Authors:  A K Das; Sanjay Kalra; Shahid Akhtar; Raman Shetty; Ajay Kumar
Journal:  Indian J Endocrinol Metab       Date:  2015 Jan-Feb

Review 3.  Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature.

Authors:  Ajay Kumar
Journal:  Indian J Endocrinol Metab       Date:  2016 May-Jun

Review 4.  Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis.

Authors:  Marcin Czech; Elżbieta Rdzanek; Justyna Pawęska; Olga Adamowicz-Sidor; Maciej Niewada; Michał Jakubczyk
Journal:  BMC Endocr Disord       Date:  2015-10-12       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.